Our novel drug class irreversibly inactivates humanity's top threat - highly infectious pandemic viruses. Maxwell's anti-infectives have been shown by multiple independent labs (including Stanford, NYU, Texas A&M, Baylor College of Medicine and others) to be rapid killers of the worst pathogens and appear safe in live animals and human cell cultures. In preclinical studies, many of Maxwell drug candidates are highly selective for pathogens over human cells, are biostable, effective at very low doses, and rapidly destroy currently untreatable pathogens. We are in preclinical stage now, preparing for human trials against the herpes virus.
Privately Funded Company
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):